Last reviewed · How we verify
NCT04464213
Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer
Phase 1 trial testing Single dose experiments in Diabetic Foot Ulcer in 43 participants. Status unknown.
1 August 2023
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 1 November 2020 |
| Primary completion | 1 August 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Single dose experiments
- Multi-dose experiments
Conditions studied
- Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 18 to 75, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designated to: 1. investigate the tolerance and safety of treatment of Human placental mesenchymal stem cells gel on Human diabetic foot ulcer. 2. learn the primary effectiveness of Human placental mesenchymal stem cells gel on Human diabetic food ulcer. 3. study the pharmacokinetics of Human placental mesenchymal stem cells gel on Human diabetic food ulcer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Diabetic Wound-Healing Science.
Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, et al · · 2021 · cited 447× · PMID 34684109 · DOI 10.3390/medicina57101072 -
Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds.
Yu X, Liu P, Li Z, Zhang Z. · · 2023 · cited 50× · PMID 37008908 · DOI 10.3389/fendo.2023.1099310 -
Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases.
Sierra-Sánchez Á, Montero-Vilchez T, Quiñones-Vico MI, Sanchez-Diaz M, et al · · 2021 · cited 33× · PMID 33768095 · DOI 10.3389/fcell.2021.643125 -
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782 -
Scaffold-based delivery of mesenchymal stromal cells to diabetic wounds.
Du S, Zeugolis DI, O'Brien T. · · 2022 · cited 27× · PMID 35987712 · DOI 10.1186/s13287-022-03115-4 -
Modulation of Mesenchymal Stem Cells for Enhanced Therapeutic Utility in Ischemic Vascular Diseases.
Elshaer SL, Bahram SH, Rajashekar P, Gangaraju R, et al · · 2021 · cited 26× · PMID 35008675 · DOI 10.3390/ijms23010249 -
An Update on the Potential of Mesenchymal Stem Cell Therapy for Cutaneous Diseases.
Li Y, Ye Z, Yang W, Zhang Q, et al · · 2021 · cited 12× · PMID 33505474 · DOI 10.1155/2021/8834590 -
Diabetic kidney disease induces transcriptome alterations associated with angiogenesis activity in human mesenchymal stromal cells.
Bian X, Conley SM, Eirin A, Zimmerman Zuckerman EA, et al · · 2023 · cited 11× · PMID 36949528 · DOI 10.1186/s13287-023-03269-9
Verify or expand the search:
- PubMed search for NCT04464213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Foot Ulcer
Currently open trials in the same condition.
- NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
- NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
- NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
- NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
- NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04464213 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 21 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04464213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing